

**Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE)
Recombinant Antibody
Catalog # APR10001**

Specification

Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) - Product Information

Application	FC, E, FTA
Primary Accession	P17813
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) - Additional Information

Target/Specificity
Endoglin / CD105

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
MMAE

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) - Protein Information

Name ENG

Synonyms END

Function
Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis (PubMed:21737454, PubMed:23300529). Required for normal structure and integrity of adult vasculature (PubMed:7894484). Regulates the migration of vascular endothelial cells (PubMed:17540773). Required for normal extraembryonic angiogenesis and for embryonic heart development (By similarity). May regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and establishment of normal vascular morphology during angiogenesis (By similarity). May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors (PubMed:1692830). Acts as a TGF-beta coreceptor and is involved in the TGF-beta/BMP signaling cascade that ultimately leads to the activation of SMAD transcription factors (PubMed:21737454, PubMed:22347366, PubMed:23300529, PubMed:8370410). Required for GDF2/BMP9 signaling through SMAD1 in endothelial cells and modulates TGFB1 signaling through SMAD3 (PubMed:21737454, PubMed:22347366, PubMed:23300529).

Cellular Location

Cell membrane; Single-pass type I membrane protein

Tissue Location

Detected on umbilical vein endothelial cells (PubMed:10625079). Detected in placenta (at protein level) (PubMed:1692830). Detected on endothelial cells (PubMed:1692830)


Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) - Images






Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) is more than 95%, determined by SEC-HPLC.



Immobilized human CD105 His at 2 µg/mL can bind Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) $EC_{50}=0.2864$ µg/mL.